Despite that, there are significant financial challenges facing the success of the current high-risk, high-cost R&D model. Moreover, companies are divesting assets that do not fit within their overall portfolios, restructuring, and rebalancing their portfolios to achieve the right balance for sustainable and profitable growth.Īccording to a recent Deloitte survey, R&D innovation is one of the top actions that 91% of life sciences organizations plan to invest in during 2023 and almost half of them are optimistic about the sector’s outlook in the coming year.
#Pharmaceutical industry overview trial#
The emergence of mRNA technology has invigorated pharmaceutical portfolios, and the outlook for mRNA vaccines includes ongoing research to develop vaccines against diseases such as HIV, Zika, and rabies, which are currently in the human trial phase.One area of potential interest for acquirers is multi-indication pharma, which refers to drugs that can treat several diseases that are linked to similar causes. In 2023, there is expected to be a potential uptick in the value of M&A deals. Mergers and acquisitions (M&A) have proven to be lucrative options for life sciences companies looking to facilitate business transformation, create ecosystem value, and disrupt the industry.Meanwhile, MedTech companies are expected to divest non-core assets in order to improve their growth profiles and create opportunities for strategic acquirers.
Vaccines and next-generation treatments, such as cell gene therapy, represent new streams of revenue for life sciences companies. Telecommunications, Media & EntertainmentĪlthough there has been a downturn in M&A activities over the past decade, life sciences companies are poised to witness an increase in M&A values in 2023 due to increased competition and the growing demand for multi-indication pharmaceutical products. Infrastructure, Transport & Regional Government
0 kommentar(er)
